Wedbush raised the firm’s price target on Apogee Therapeutics (APGE) to $95 from $90 and keeps an Outperform rating on the shares. The firm notes the company reported earnings and reiterated guidance to March data for 52-week maintenance data from the Phase 2 APEX study of zumilokibart in atopic dermatitis. Induction data will follow in Q2 2026 for the dose-ranging portion of the trial, which should build on earlier results showing an exposure-response relationship. Wedbush expects Apogee will proceed to Phase 3 trials in the second half of 2026. Additional upside is possible from APG279 in the second half of 2026, the firm adds.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability
- Apogee Therapeutics reports FY25 net loss $255.8M vs. $182.1M last year
- Apogee Therapeutics sees cash runway into 2H28
- Apogee selloff on Sanofi data brings opportunity, says UBS
- Apogee Therapeutics selloff on Sanofi data overdone, says Citi